Navigation Links
Abbott to Present Data on Market-Leading XIENCE V® and Promising Vascular Pipeline at TCT 2010
Date:9/16/2010

Abbott to Present Data on Market-Leading XIENCE V® and Promising Vascular Pipeline... -- ABBOTT PARK, Ill., Sept. 16 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Trade Show News Click to view news release full screen  

Abbott to Present Data on Market-Leading XIENCE V® and Promising Vascular Pipeline at TCT 2010

   

-- XIENCE V Data From the SPIRIT IV Trial to be Presented as a Late Breaking Trial on Sept. 23-- Abbott's Vascular Pipeline Presentations to Include Data on the MitraClip® System and the Bioresorbable Vascular Scaffold

ABBOTT PARK, Ill., Sept. 16 /PRNewswire-FirstCall/ --  Abbott (NYSE: ABT) today announced the company's schedule of key data presentations at the Cardiovascular Research Foundation's 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C., to be held Sept. 21 – 25. Highlights include late-breaking two-year data from SPIRIT IV, one of the largest randomized, head-to-head clinical trials between two drug eluting stents – Abbott's XIENCE V® Everolimus Eluting Coronary Stent System and Boston Scientific's TAXUS® Express Paclitaxel-Eluting Coronary Stent System. In addition, the company will present data on two key pipeline products: the first-of-its-kind MitraClip® system, an investigational device in the United States; and the bioresorbable vascular scaffold (BVS), currently under clinical investigation outside the United States.

"We continue to strengthen our leadership position in the treatment of vascular disease with significant new data that support our market-leading XIENCE V stent, which has become the gold standard of drug eluting stents around the world," said Robert Hance, senior vice president, vascular, Abbott. "We also continue to make progress with our industry leading vascular pipeline, and we look forward to presenting additional data on our key pipeline products, including the MitraClip system and our bioresorbable vascular scaffold."

Key presentations are as follows (all times are Eastern):

SPIRIT IV: Two-year results from SPIRIT IV will be presented by Gregg W. Stone, M.D., professor of medicine at Columbia University Medical Center, during the first late-breaking clinical trials session at 11 a.m. in the Main Arena on Thursday, Sept. 23. SPIRIT IV is one of the largest randomized clinical trials ever conducted that compares two drug eluting stents.

The study enrolled 3,690 patients – including more than 1,000 patients with diabetes. Dr. Stone is the principal investigator of the SPIRIT IV trial.

SPIRIT III: Four-year results from SPIRIT III will be presented during the Scientific Symposia starting at 1 p.m. on Wednesday, Sept. 22. SPIRIT III is a prospective, multi-center, randomized, single-blind, controlled clinical trial comparing XIENCE V to TAXUS in 1,002 patients (669 XIENCE V patients and 333 TAXUS patients) with either one or two de novo coronary artery lesions.

XIENCE V USA: One-year results from XIENCE V USA, including subset data, will be presented during the Scientific Symposia starting at 3:30 p.m. on Wednesday, Sept. 22. XIENCE V USA is a post-market, real-world, single-arm registry evaluating outcomes in more than 5,000 XIENCE V patients based in the U.S., with follow-up out to five years. Subset data presented at TCT will include information on patient quality of life after receiving a XIENCE V stent and data on the safety and efficacy of XIENCE V in real-world patients with acute myocardial infarction.

EVEREST II: During the Scientific Symposia starting at 3:30 p.m. on Wednesday, Sept. 22, a number of presentations will review new data from EVEREST II, the landmark trial of the MitraClip system, a first-of-its-kind, catheter-based device for mitral valve repair. In addition, the MitraClip system will be highlighted during the "Hottest Topic of 2010: Transcatheter Valve Therapy" session starting at 9:30 a.m. on Thursday, Sept. 23, and the "Best of the Best TCT 2010 Abstracts" starting at 3:16 p.m. on Friday, Sept. 24. The MitraClip system received CE Mark in March 2008. In the U.S., the MitraClip system is limited by federal law to investigational use only and is not available for sale. The MitraClip system is currently under review for approval by the U.S. Food and Drug Administration.

ABSORB: Nine-month data on 45 patients and six-month data on all 101 patients from the second phase of ABSORB will be presented on Wednesday, Sept. 22. The ABSORB trial is evaluating Abbott's bioresorbable vascular scaffold (BVS), which aims to restore blood flow by opening a clogged vessel and providing support until it is healed. Once the vessel can remain open without the extra support, the BVS is designed to be slowly metabolized and eventually resorbed by the body. Abbott's BVS device is under clinical investigation outside the U.S. The device is currently in development at Abbott Vascular and not available for sale.

As part of its commitment to ongoing medical education, Abbott is providing support for a number of symposia on key topics for interventional cardiologists throughout the conference. In addition, the Abbott booth (#1456) will feature the company's vascular pipeline, as well as resources and programs for physicians and patients.

About XIENCE VAbbott's market-leading XIENCE V drug eluting stent is marketed in the U.S., Europe, Japan and other international markets.

Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its anti-proliferative properties.

XIENCE V is indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions (lesions less than or equal to 28 mm) with reference vessel diameters of 2.5 mm to 4.25 mm. Additional information about XIENCE V, including important safety information, is available online at www.xiencev.com or www.abbottvascular.com/en_US/content/document/eIFU_XienceV.pdf.

About Abbott VascularAbbott Vascular is a global leader in cardiac and vascular care with market-leading products and an industry-leading pipeline. Abbott Vascular offers a comprehensive cardiac and vascular devices portfolio, including products for coronary artery disease, vessel closure, endovascular disease, and structural heart disease.

About Abbott Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs nearly 90,000 people and markets its products in more than 130 countries.  

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.


'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
2. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
3. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
4. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
5. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
6. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
7. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
8. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
9. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... to the Centers for Disease Control and Prevention (CDC), influenza vaccination ... is helping communities across Massachusetts , Connecticut ... flu shots through the end of the month. *Some exclusions ... ... shot is by the end of October, according to the Centers for ...
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and ... financial results for the third quarter of 2017 on ... conference call on that day with the investment community ... The conference call will begin at 9 ... can access a live webcast of the conference call ...
(Date:10/2/2017)... The Rebound mobile app is poised to become a vital ... prescription drug addiction. The app empowers users to develop an ... their dosage in a safe, controlled manner while maximizing well-being. ... 100,000 people to sign up will enjoy 3 months of ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history of ... Brink” is the creation of published author, William Nowers. Captain Nowers and his ... veteran, he spent thirty years in the Navy. Following his career as a ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
Breaking Medicine News(10 mins):